Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Location Directory

Clinical trials in Aurora, Colorado

This page shows live ClinicalTrials.gov search results for Aurora, Colorado, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:32 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
7450
Shown on this page
12
Current sort
Recently updated
Location scope
Aurora, CO
Filters apply within this location only.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this location

These controls apply only within Aurora, Colorado. Default order is Recently updated. Use recruitment status if you want to focus on actively recruiting studies in this location.

Reset location filters
Clear filters
Showing 517–528 of 7,450 matching trials in Aurora, CO.
Live ClinicalTrials.gov results.
Local directory summary panels are hidden while filters are applied so the page stays focused on the filtered live results.

Institutions in Aurora

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

Live official records

Open in full search
Recruiting Phase 2Phase 3 Interventional

FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC

NCT06788990
View directory record Official record
Conditions
Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
Interventions
Ficerafusp alfa, Pembrolizumab (KEYTRUDA®), Placebo
Drug
Lead sponsor
Bicara Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
55
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 41 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Nov 15, 2026, 7:32 AM EST
Not yet recruiting Phase 1 Interventional

A Study to Evaluate the Safety and Antiviral Activity of Two Human Monoclonal Antibodies (VRC07-523LS and PGT121.414.LS) During Analytic Treatment Interruption in Participants Living With HIV Who Initiated ART During Acute/Early HIV-1 Infection

NCT06987318
View directory record Official record
Conditions
HIV-1-infection
Interventions
VRC07-523LS, PGT121.414.LS
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
10
States / cities
Birmingham, Alabama • San Diego, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Nov 15, 2026, 7:32 AM EST
Recruiting Phase 4 Interventional

Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention

NCT06909565
View directory record Official record
Conditions
Percutaneous Coronary Intervention, Peripheral Endovascular Intervention
Interventions
Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, Normal Saline (Placebo)
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
6,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
149
States / cities
Alexander City, Alabama • Birmingham, Alabama • Huntsville, Alabama + 131 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Nov 15, 2026, 7:32 AM EST
Active, not recruiting Phase 3 Interventional

A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)

NCT05668988
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
sunvozertinib, Pemetrexed+carboplatin
Drug
Lead sponsor
Dizal Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
324 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
15
States / cities
Glendale, California • Vallejo, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Nov 15, 2026, 7:32 AM EST
Recruiting Not applicable Interventional

Starlight Cardiovascular Lifeline Ductus Arteriosus Stent IDE Study

NCT07114718
View directory record Official record
Conditions
Congenital Heart Disease, Congenital Heart Disease (CHD)
Interventions
Ductus Arteriosus Stent
Device
Lead sponsor
Starlight Cardiovascular Inc
Industry
Eligibility
1 Minute to 6 Months
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
11
States / cities
Los Angeles, California • San Diego, California • Stanford, California + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Nov 15, 2026, 7:32 AM EST
Enrolling by invitation Not applicable Interventional

EXCOR Active Driving System for the EXCOR Pediatric VAD IDE Study

NCT05610787
View directory record Official record
Conditions
Heart Failure, Transplant; Failure, Heart, Congenital Heart Disease
Interventions
EXCOR Active Driving System for Pediatric VAD
Device
Lead sponsor
Berlin Heart, Inc
Industry
Eligibility
Up to 21 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
17
States / cities
Los Angeles, California • Palo Alto, California • Aurora, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Nov 15, 2026, 7:32 AM EST
Recruiting Phase 4 Interventional

De-implementing Inhaled Nitric Oxide for Congenital Diaphragmatic Hernia

NCT05213676
View directory record Official record
Conditions
Congenital Diaphragmatic Hernia
Interventions
Inhaled Nitric Oxide (iNO) use, De-implementation of Inhaled Nitric Oxide (iNO) use
Drug · Other
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
0 Months to 1 Month
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
19
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Irvine, California + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Nov 15, 2026, 7:32 AM EST
Recruiting No phase listed Observational

Observational Safety Study in Women With Neuromyelitis Optica Spectrum Disorder (NMOSD) Exposed to UPLIZNA® During Pregnancy

NCT05909761
View directory record Official record
Conditions
Neuromyelitis Optica Spectrum Disorder, Pregnancy Related
Interventions
UPLIZNA
Drug
Lead sponsor
Amgen
Industry
Eligibility
15 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2032
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Nov 15, 2026, 7:32 AM EST
Recruiting Phase 2 Interventional

A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.

NCT07652658
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis (IPF)
Interventions
Placebo for AZD8965, AZD8965 low dose, AZD8965 medium dose, AZD8965 high dose
Other · Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years and older
Enrollment
359 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
36
States / cities
Birmingham, Alabama • Phoenix, Arizona • Loma Linda, California + 30 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Nov 15, 2026, 7:32 AM EST
Recruiting Phase 1Phase 2 Interventional

A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)

NCT06428409
View directory record Official record
Conditions
Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer
Interventions
Sacituzumab tirumotecan, Fluorouracil (5-FU), Leucovorin (LV) or levoleucovorin, Rescue medication, Supportive care measures, Cisplatin, Pembrolizumab
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
13
States / cities
Los Angeles, California • Aurora, Colorado • Washington D.C., District of Columbia + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Nov 15, 2026, 7:32 AM EST
Recruiting No phase listed Observational

Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution

NCT06131801
View directory record Official record
Conditions
Hematologic Malignancy, Leukemia, Lymphoma, Acute Lymphocytic Leukemia, ALL, Acute Myelogenous Leukemia, AML, Chronic Myelogenous Leukemia, CML, Myeloproliferative Neoplasm, Non Hodgkin Lymphoma, Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Burkitt Lymphoma, T-cell Lymphoma, B Cell Lymphoma, Peripheral T Cell Lymphoma, Cutaneous B-Cell Lymphoma
Interventions
1. Drug: The Venetoclax PK study is collecting bodily fluid samples (ie., whole blood and optional cerebrospinal fluid) of patients prescribed venetoclax as crushed tablets per standard of care.
Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
0 Years to 38 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
6
States / cities
Aurora, Colorado • Atlanta, Georgia • Cincinnati, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Nov 15, 2026, 7:32 AM EST
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Direct-to-patient Teledermatology and Computer-assisted Diagnosis

NCT05128006
View directory record Official record
Conditions
New Patient Use of Teledermatology Mobile App
Interventions
New patient teledermatology visit
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
63,200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
3
States / cities
San Francisco, California • Aurora, Colorado • Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Nov 15, 2026, 7:32 AM EST